Quantitative Imaging for Evaluation of Responses to Cancer Therapies promotes the research and development of quantitative imaging methods to measure tumor response to therapies in clinical trial settings with the overall goal of facilitating clinical decision making. Projects include the development and adaptation/implementation of quantitative imaging methods, imaging protocols, software solutions/tools (using existing commercial imaging platforms and instrumentation), and application of these methods in current and planned phase 1 and 2 clinical therapy trials. The projects are focusing on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions (IGI). The goals require multidisciplinary efforts, including oncologists as well as clinical and basic imaging scientists and the involvement of industrial partners in the development and adaptation/implementation of quantitative imaging methods to aid cancer therapies.
This network is one of several being developed within the Cancer Imaging Program. The main emphasis is on the support of the development and adaptation/implementation of quantitative imaging endpoints (including imaging methods and related software tools research, and/or informatics infrastructure). Any related clinical trials are not supported under this program.
Centers of imaging excellence have been selected through the National Institute of Health peer review process and more will be added as they pass through peer review. Five working groups address common issues to the various programs, including data collection, data evaluation, informatics, and potential clinical trials have been established. Various program staff from the National Cancer Institute (NCI) oversee the network through monthly phone calls. The network organizes activities such as consensus publications, cross-network activities, associate membership in the network, and annual face-to-face meetings.
To clarify rules of engagement and to encourage meaningful data sharing, QIN adopted a data sharing policy in November 2013. The spirit of this policy is one of collaboration and flexibility intended to introduce a minimal amount of oversight and/or committee work to QIN members. The QIN provides commercial and academic investigators with an opportunity to access data collected as part of QIN studies for purposes that are consistent with the missions of the QIN and the NCI. All QIN members, associate/affiliate members, external collaborators, and companies are made aware of the guiding principles of the QIN Resource Sharing Policy. The objective of the data sharing policy is to help maximize effectiveness by fostering an environment of collaboration and sharing, while addressing concerns of data being used without consent, either by a member of the QIN or an external collaborator. Concerns about inappropriate data use could hinder the multi-center collaborations within the QIN.
The guiding principles of the QIN data sharing policy are as follows:
To facilitate data sharing, the QIN increasingly relies on The Cancer Imaging Archive (TCIA) as a resource, which addresses many of the principles set forth in the data sharing policy. Most importantly, TCIA provides a mechanism for access-controlled data sharing and extensive de-identification services, which comply with Health Insurance Portability and Accountability Act (HIPAA) regulations. This drastically reduces the burden on QIN sites when sharing their data. More information can be found in the following paper describing QIN data sharing activities: